Loading...
Loading...
SGMT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 7,388.0K |
| Operating I/L | -7,388.0K |
| Other Income/Expense | 193.0K |
| Interest Income | 193.0K |
| Pretax | -7,195.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -7,195.0K |
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors for the treatment of diseases related to dysfunctional lipid metabolism pathways. Its lead drug candidate, Denifanstat, targets nonalcoholic steatohepatitis and acne, while the company is also developing TVB-3567 for various cancer types. By creating and advancing these FASN inhibitors, Sagimet Biosciences aims to generate revenue through the commercialization of innovative therapeutics that address unmet medical needs in the fields of liver disease and oncology.
